Eric Blankemeyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eric Blankemeyer has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Amulya Sreekumar
Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
8 shared publications - Anupma Nayak
Hospital of the University of Pennsylvania, Philadelphia, PA, USA
8 shared publications - Charles-Antoine Assenmacher
University of Pennsylvania, Philadelphia, PA
8 shared publications - Christopher J. Sterner
Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
8 shared publications - David A. Mankoff
Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
8 shared publications - Dhruv K. Pant
Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
8 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
Supplementary Figure S3 shows Sox5 shRNA knockdown efficiency, proliferation and apoptosis rates in vitro and in vivo, and Sox5 sgRNA editing efficiency in nucleofected D2.OR cells
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
Supplementary Figure S3 shows Sox5 shRNA knockdown efficiency, proliferation and apoptosis rates in vitro and in vivo, and Sox5 sgRNA editing efficiency in nucleofected D2.OR cells
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
Supplementary Figure S4 shows chondrogenesis and osteogenesis signature enrichment during dormancy in vitro in MTB/TAN cells as well as GFP positivity relative to Alcian blue staining
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
Supplementary Figure S4 shows chondrogenesis and osteogenesis signature enrichment during dormancy in vitro in MTB/TAN cells as well as GFP positivity relative to Alcian blue staining
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
Supplementary Figure S5 shows μCT and [18F]NaF PET in MTB/TAN cells as well as GFP positivity relative to Alcian blue staining
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
Supplementary Figure S5 shows μCT and [18F]NaF PET in MTB/TAN cells as well as GFP positivity relative to Alcian blue staining
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
Recurrent breast cancer accounts for most disease-associated mortality and can develop decades after primary tumor therapy. Recurrences arise from residual tumor cells (RTC) that can evade therapy in a dormant state; however, the mechanisms enforcing dormancy in RTCs are poorly understood. CRISPR−Cas9 screening identified the transcription factors SOX5 and SOX6 as functional regulators of tumor recurrence. Loss of SOX5 accelerated recurrence at both local and metastatic sites and promoted dormancy escape in both therapy-associated and microenvironment-induced contexts. Remarkably, SOX5 drove dormant RTCs to adopt a cartilage-dependent bone development program, termed endochondral ossification, which was confirmed by [18F]NaF–positron emission tomography (PET) imaging and reversed in recurrent tumors escaping dormancy. Consistent with findings in mice, osteochondrogenic expression signatures in patients were enriched in residual disease following neoadjuvant therapy, and their enrichment in primary breast cancers predicted improved recurrence-free survival. These findings identify SOX5-dependent mesodermal transdifferentiation as an adaptive mechanism that prevents recurrence by reinforcing tumor cell dormancy.Significance:Our study reveals a SOX5-mediated endochondral ossification program that maintains transdifferentiated breast cancer RTCs in a dormant state and predicts recurrence risk. Incorporating [18F]NaF-PET as an imaging-based readout of this process could stratify patients for minimal residual disease−targeting or dormancy-enforcing treatments, offering a transformative approach to personalize care for breast cancer survivors.See related commentary by Gonçalves and Correia, p. 626
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
Recurrent breast cancer accounts for most disease-associated mortality and can develop decades after primary tumor therapy. Recurrences arise from residual tumor cells (RTC) that can evade therapy in a dormant state; however, the mechanisms enforcing dormancy in RTCs are poorly understood. CRISPR−Cas9 screening identified the transcription factors SOX5 and SOX6 as functional regulators of tumor recurrence. Loss of SOX5 accelerated recurrence at both local and metastatic sites and promoted dormancy escape in both therapy-associated and microenvironment-induced contexts. Remarkably, SOX5 drove dormant RTCs to adopt a cartilage-dependent bone development program, termed endochondral ossification, which was confirmed by [18F]NaF–positron emission tomography (PET) imaging and reversed in recurrent tumors escaping dormancy. Consistent with findings in mice, osteochondrogenic expression signatures in patients were enriched in residual disease following neoadjuvant therapy, and their enrichment in primary breast cancers predicted improved recurrence-free survival. These findings identify SOX5-dependent mesodermal transdifferentiation as an adaptive mechanism that prevents recurrence by reinforcing tumor cell dormancy.Significance:Our study reveals a SOX5-mediated endochondral ossification program that maintains transdifferentiated breast cancer RTCs in a dormant state and predicts recurrence risk. Incorporating [18F]NaF-PET as an imaging-based readout of this process could stratify patients for minimal residual disease−targeting or dormancy-enforcing treatments, offering a transformative approach to personalize care for breast cancer survivors.See related commentary by Gonçalves and Correia, p. 626
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
Supplementary Figure S1 shows sgRNA distribution at each of the time points during disease progression as well as clonal enrichment for sgRNAs targeting Sox5 and Sox6 in MTB/TAN cells
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
Supplementary Figure S1 shows sgRNA distribution at each of the time points during disease progression as well as clonal enrichment for sgRNAs targeting Sox5 and Sox6 in MTB/TAN cells
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
List of targets and sgRNAs used in the custom CRISPR-Cas9 screen. sgRNAs with validated editing efficiency are highlighted
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
List of targets and sgRNAs used in the custom CRISPR-Cas9 screen. sgRNAs with validated editing efficiency are highlighted
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
Supplementary Figure S2 shows Sox5 and Sox6 sgRNA editing efficiency, primary tumor and recurrent tumor growth rate at the orthotopic and metastatic site in MTB/TAN cells
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
Supplementary Figure S2 shows Sox5 and Sox6 sgRNA editing efficiency, primary tumor and recurrent tumor growth rate at the orthotopic and metastatic site in MTB/TAN cells
- 11 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (4) , 781-799
Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
Recurrent breast cancer accounts for most disease-associated mortality and can develop decades after primary tumor therapy. Recurrences arise from residual tumor cells (RTC) that can evade therapy in a dormant state; however, the mechanisms enforcing dormancy in RTCs are poorly understood. CRISPR−Cas9 screening identified the transcription factors SOX5 and SOX6 as functional regulators of tumor recurrence. Loss of SOX5 accelerated recurrence at both local and metastatic sites and promoted dormancy escape in both therapy-associated and microenvironment-induced contexts. Remarkably, SOX5 drove dormant RTCs to adopt a cartilage-dependent bone development program, termed endochondral ossification, which was confirmed by [18F]NaF–positron emission tomography (PET) imaging and reversed in recurrent tumors escaping dormancy. Consistent with findings in mice, osteochondrogenic expression signatures in patients were enriched in residual disease following neoadjuvant therapy, and their enrichment in primary breast cancers predicted improved recurrence-free survival. These findings identify SOX5-dependent mesodermal transdifferentiation as an adaptive mechanism that prevents recurrence by reinforcing tumor cell dormancy. Significance: Our study reveals a SOX5-mediated endochondral ossification program that maintains transdifferentiated breast cancer RTCs in a dormant state and predicts recurrence risk. Incorporating [18F]NaF-PET as an imaging-based readout of this process could stratify patients for minimal residual disease−targeting or dormancy-enforcing treatments, offering a transformative approach to personalize care for breast cancer survivors. See related commentary by Gonçalves and Correia, p. 626
- 11 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (4) , 781-799
Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy
Recurrent breast cancer accounts for most disease-associated mortality and can develop decades after primary tumor therapy. Recurrences arise from residual tumor cells (RTC) that can evade therapy in a dormant state; however, the mechanisms enforcing dormancy in RTCs are poorly understood. CRISPR−Cas9 screening identified the transcription factors SOX5 and SOX6 as functional regulators of tumor recurrence. Loss of SOX5 accelerated recurrence at both local and metastatic sites and promoted dormancy escape in both therapy-associated and microenvironment-induced contexts. Remarkably, SOX5 drove dormant RTCs to adopt a cartilage-dependent bone development program, termed endochondral ossification, which was confirmed by [18F]NaF–positron emission tomography (PET) imaging and reversed in recurrent tumors escaping dormancy. Consistent with findings in mice, osteochondrogenic expression signatures in patients were enriched in residual disease following neoadjuvant therapy, and their enrichment in primary breast cancers predicted improved recurrence-free survival. These findings identify SOX5-dependent mesodermal transdifferentiation as an adaptive mechanism that prevents recurrence by reinforcing tumor cell dormancy. Significance: Our study reveals a SOX5-mediated endochondral ossification program that maintains transdifferentiated breast cancer RTCs in a dormant state and predicts recurrence risk. Incorporating [18F]NaF-PET as an imaging-based readout of this process could stratify patients for minimal residual disease−targeting or dormancy-enforcing treatments, offering a transformative approach to personalize care for breast cancer survivors. See related commentary by Gonçalves and Correia, p. 626